Digestive System Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A malignant neoplasm that arises from the epithelium of any part of the digestive system. Representative examples include colorectal carcinoma, esophageal carcinoma, and pancreatic carcinoma. 
Digestive system carcinomas most frequently harbor alterations in TP53, APC, KRAS, PIK3CA, and SMAD4 .
TP53 Mutation, APC Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and KRAS Mutation are the most common alterations in digestive system carcinoma .
There are 4 clinical trials for digestive system carcinoma, of which 2 are open and 2 are completed or closed. Of the trials that contain digestive system carcinoma as an inclusion criterion, 3 are phase 1 (1 open) and 1 is phase 2 (1 open).
ERBB2, GUCY2C, and HER2 are the most frequent gene inclusion criteria for digestive system carcinoma clinical trials .
Tak-164, camrelizumab, and capecitabine are the most common interventions in digestive system carcinoma clinical trials.
Significant Genes in Digestive System Carcinoma
ERBB2 is altered in 6.32% of digestive system carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and digestive system carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for digestive system carcinoma, of which 0 are open and 1 is closed. Of the trial that contains UGT1A1 status and digestive system carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.